Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ALK rearrange |
Therapy | Crizotinib |
Indication/Tumor Type | lymphoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK rearrange | lymphoma | predicted - sensitive | Crizotinib | Phase I | Actionable | In a Phase Ib trial (PROFILE 1013), Xalkori (crizotinib) treatment resulted in an objective response rate of 52.9% (9/17, 8 complete responses, 1 partial response) and stable disease in 17.6% (3/17) of patients with advanced ALK-positive lymphomas, with a median duration of response of 135.9 weeks in (PMID: 29352732; NCT00939770). | 29352732 |
PubMed Id | Reference Title | Details |
---|---|---|
(29352732) | Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. | Full reference... |